Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06360250
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-11
First Post:
2024-04-07
Brief Title:
Safety Tolerability Pharmacokinetics Pharmacodynamics and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 B86 Injection Combination Formulation
Sponsor:
Organization:
Changchun BCHT Biotechnology Co
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
190
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| EARLY_PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: